SMC combination therapy for the treatment of cancer
AssigneeChildren's Hospital of Eastern Ontario Research Institute Inc.
InventorsRobert G. Korneluk, Eric C. Lacasse, Shawn T. Beug, Vera A. Tang
Life of this patent
Estimating the term…
Abstract
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
Claims6
A composition comprising LCL161 or a pharmaceutically acceptable salt thereof and a vesicular stomatitis virus (VSV) Δ51.
A kit comprising LCL161 or a pharmaceutically acceptable salt thereof and a VSVΔ51.
Dependencies are inferred from the claim text.